In a statement for the record for the House Energy and Commerce Health Subcommittee Committee hearing, Premier underscored how drug shortages threaten the security of the pharmaceutical supply chain, jeopardizing patient care and adding tremendous costs to the healthcare system. The heavy reliance on foreign manufacturing of active pharmaceutical ingredients (API) and raw materials results in downstream drug shortages when a foreign manufacturer fails to meet cGMP or exits the market. In addition, the extent and duration of API or raw material shortages is unknown and results in downstream impact on hoarding and the gray market. Premier urged Committee members to support the bipartisan solutions to address these and other root causes of drug shortages that are contained in the Mitigating Emergency Drug Shortages (MEDS) Act (S. 2723).
About Premier, Inc.
Premier Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of more than 4,000 U.S. hospitals and health systems and approximately 175,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost. Premier plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier’s news and investor sites on www.premierinc.com; as well as Twitter, Facebook, LinkedIn, YouTube, Instagram and Premier’s blog for more information about the company.